FCRL5 and plasma cell myeloma: These findings extend prior reports that bsAbs targeting membrane proximal epitopes in the FcRH5 surface marker on myeloma cells or in the melanoma-associated chondroitin sulfate proteoglycan (MCSP) on melanoma cells, outperform those targeting membrane distal epitopes49,50.